Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.

@article{Ghobrial2014LongtermRO,
  title={Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.},
  author={Irene M Ghobrial and Thomas E Witzig and Morie A Gertz and Betsy R Laplant and Suzanne R. Hayman and John K. Camoriano and Martha Lacy and Peter Leif Bergsagel and Stacey Chuma and Daniel Deangelo and Steven P Treon},
  journal={American journal of hematology},
  year={2014},
  volume={89 3},
  pages={237-42}
}
Everolimus is an oral raptor mTOR inhibitor and has shown activity in patients with Waldenstrom's macroglobulinemia (WM). This study examines a large cohort of patients with relapsed/refractory WM with long-term follow up for survival. Patients were eligible if they had measurable disease, a platelet count >75,000 x 10(6)/L, an absolute neutrophil count >1,000 x 10(6)/L. Patients received everolimus 10 mg PO daily and were evaluated monthly. A success was defined as a complete or partial… CONTINUE READING
24 Citations
49 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Multicenter phase 2 trial of rituximab for Waldenstrom RESEARCH ARTICLE Everolimus in Waldenstrom Macroglobulinemia doi:10.1002/ajh.23620

  • MA Gertz, M Rue, E Blood
  • American Journal of Hematology,
  • 2014

Similar Papers

Loading similar papers…